Taxanes: Impact on pancreatic cancer

Anti-Cancer Drugs

Volumn 25, Issue 5, 2014, Pages 584-592

  Chioreana, E Gabriela ^a   Von Hoffb, Daniel D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Docetaxel; Nanoparticle bound paclitaxel; Paclitaxel; Pancreatic cancer; Taxanes

Indexed keywords

CREMOPHOR; CYTIDINE DEAMINASE; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; NANOPARTICLE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; GOLD STANDARD; HUMAN; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT THERAPY; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; TAXOIDS;

EID: 84908380553     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000073     Document Type: Review

References (108)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 11-11
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15:2403-2413.
3. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27:5513-5518.
4. Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Marten A, Winkelmann C, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: Final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013; 62:751-759.
5. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952.
6. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:3778-3785.
7. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617-3622.
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
9. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-483.
10. Komar G, Kauhanen S, Liukko K, Seppanen M, Kajander S, Ovaska J, et al. Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15:5511-5517.
11. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 2013; 108:1-8.
12. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011; 60:861-868.
13. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978; 62:1219-1222.
14. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: Implications of the differences. Oncologist 2004; 9 (Suppl 2):3-8.
15. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012; 2:260-269.
16. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011; 29:4548-4554.
17. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-1703.
18. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-1806.
19. Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, et al. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012; 18:6519-6530.
20. Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999; 80:438-443.
21. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study. J Clin Oncol 1999; 17:1779-1785.
22. Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, et al. A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36:1016-1025.
23. Cascinu S, Gasparini G, Catalano V, Silva RR, Pancera G, Morabito A, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999; 10:1377-1379.
24. Stathopoulos GP, Mavroudis D, Tsavaris N, Kouroussis C, Aravantinos G, Agelaki S, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12:101-103.
25. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94:97-103.
26. Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study. Oncology 2003; 65:218-223.
27. Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology 2004; 66:303-309.
28. Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: Randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 2005; 23:9250-9256.
29. Ridwelski K, Fahlke J, Kuhn R, Hribaschek A, Kettner E, Greiner C, et al. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma. Eur J Surg Oncol 2006; 32:297-302.
30. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009; 27:5506-5512.
31. Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, et al. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer J 2007; 13:257-262.
32. Fine R, Lee Y, Sherman WH, Gulati AP, Oberstein PE, Chu K, et al. Prospective phase II trial of GTX in metastatic pancreatic cancer: Laboratory and clinical studies [Gastrointestinal Cancers Symposium abstracts]. J Clin Oncol 2012; 34 (Suppl):209.
33. Fine RL, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, et al. PhaseII trial of GTX chemotherapy in metastatic pancreatic cancer [ASCO meeting abstracts]. J Clin Oncol 2009; 27 (Suppl):4623.
34. Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, et al. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol 2011; 67:511-517.
35. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012; 69:415-424.
36. Xenidis N, Chelis L, Amarantidis K, Chamalidou E, Dimopoulos P, Courcoutsakis N, et al. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: A phase II study. Cancer Chemother Pharmacol 2012; 69:477-484.
37. Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 2012; 69:115-123.
38. Cereda S, Reni M. Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 2008; 20:509-512.
39. Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: A retrospective study. Anticancer Res 2010; 30:2905-2909.
40. Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006; 71:159-163.
41. Brell JM, Matin K, Evans T, Volkin RL, Kiefer GJ, Schlesselman JJ, et al. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009; 76:270-274.
42. Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, et al. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 2009; 9:404-409.
43. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: Results of a phase II study. Cancer Invest 2008; 26:47-52.
44. Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: The final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67:361-368.
45. Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, et al. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: A retrospective analysis. Cancer Chemother Pharmacol 2012; 69:425-430.
46. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
47. Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: Rationale and clinical results. Clin Breast Cancer 2002; 2:287-293.
48. Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002; 20:2616-2623.
49. Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 2001; 37:2310-2323.
50. Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, et al. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 2002; 13:583-593.
51. Engblom P, Rantanen V, Kulmala J, Helenius H, Grenman S. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 1999; 79:286-292.
52. Maeda S, Sugiura T, Saikawa Y, Kubota T, Otani Y, Kumai K, et al. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 2004; 95:679-684.
53. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis. Cancer Chemother Pharmacol 2008; 61:167-175.
54. Ettrich T, Goetz VW, Gress T, Michl P, Geissler M, Hebart H, et al. DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas [ASCO meeting abstracts]. J Clin Oncol 2013; 31 (Suppl):4034.
55. Inoue Y, Koh W, Sinanan M, Byrd DR, Park JO, Mann GN, et al. Multimodality neoadjuvant therapy for resectable pancreas cancer. Gastrointestinal Cancers Symposium 2010; abstract #261.
56. Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. JSurgOncol2011; 104:155-161.
57. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994; 86:441-446.
58. Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 2010; 36:987-992.
59. Oberic L, Viret F, Baey C, Ychou M, Bennouna J, Adenis A, et al. Docetaxeland 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: A FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Radiat Oncol 2011; 6:124.
60. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19:351-386.
61. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-1259.
62. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42:665-685.
63. Gebbia N, Gebbia V. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur J Cancer 1996; 32 A:1822-1823.
64. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colonystimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study. J Clin Oncol 1997; 15:2414-2419.
65. Lam AP, Sparano JA, Vinciguerra V, Ocean AJ, Christos P, Hochster H, et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010; 33:121-124.
66. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, et al. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2012; 70:875-881.
67. Leichman LP, O'Neil BH, Berlin J, Weekes CD, Ames P, McKinley M, et al. A phase IB study of erlotinib in combination with gemcitabine and nabpaclitaxelin patients with previously untreated advanced pancreatic cancer: An academic GI cancer consortium (AGICC) [ASCO meeting abstracts]. J Clin Oncol 2012; 30 (Suppl):4052.
68. El-Khoueiry AB, Iqbal S, Lenz H, Gitlitz BJ, Yang D, Cole S, et al. A phase I study of two different schedules of nab-paclitaxel with ascending doses of vandetanib with expansion in patients with pancreatic cancer [ASCO meeting abstracts]. J Clin Oncol 2011; 29 (Suppl):4124.
69. Lohr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase II trial. Ann Oncol 2012; 23:1214-1222.
70. Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, et al. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 2010; 28:186-194.
71. Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635-638.
72. Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, et al. Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: A retrospective study. Jpn J Clin Oncol 2010; 40:1135-1138.
73. Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabinerefractory pancreatic cancer: A retrospective study. Int J Clin Oncol 2011; 16:539-545.
74. Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol 2009; 63:529-533.
75. Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013; 36:151-156.
76. Ernani V, Akunyili II, Hosein P, Macintyre J, Rocha Lima CMS. Gemcitabine and nab-paclitaxel in patients with refractory advanced pancreatic cancer [Gastrointestinal Cancers Symposium meeting abstracts]. J Clin Oncol 2012; 30 (Suppl 4):373.
77. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20:2537-2544.
78. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001; 49:1275-1279.
79. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004; 27:51-56.
80. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, et al. Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9:2335-2341.
81. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 2010; 126:1235-1245.
82. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012; 12:39-50.
83. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004; 10:3708-3716.
84. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
85. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8:1038-1044.
86. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release 2013; 170:365-372.
87. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12:1317-1324.
88. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003; 22:5021-5030.
89. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25:319-325.
90. Yardley DA, Daniel BR, Inhorn RC, Vazquez ER, Trieu VN, Motamed K, et al. SPARC microenvironment signature analysis of a phase II trial of neoadjuvant gemcitabine, epirubicin, and nab-paclitaxel in locally advanced breast cancer [ASCO meeting abstracts]. J Clin Oncol 2010; 28 (Suppl):10574.
91. Markovic S, Suman V, Trieu VN, Liu X, Yeh W, Hwang L, et al. Tumor SPARC microenvironment signature and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E [ASCO meeting abstracts]. J Clin Oncol 2010; 28 (Suppl):8578.
92. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6:1186-1197.
93. Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 2013; 109:926-933.
94. Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2013 [Epub ahead of print].
95. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-1825.
96. Ramanathan R, Lee P, Leach JW, Anthony SP, Weiss GJ, Rosen PJ, et al. Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer [Gastrointestinal Cancers Symposium abstracts]. J Clin Oncol 2012; 30 (Suppl):233.
97. Hingorani SR, Harris WP, Beck T, Berdov BA, Wagner SA, Pshevlotsky EM, et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer [ASCO meeting abstracts]. J Clin Oncol 2013; 31 (Suppl):4010.
98. Ramfidis VS, Syrigos KN, Saif MW. New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. JOP 2013; 14:344-346.
99. MacKenzie S, Zeh H, McCahill LE, Sielaff TD, Bahary N, Gribbin TE, et al. A pilot phase II multicenter study of nab-paclitaxel and gemcitabine as preoperative therapy for potentially resectable pancreatic cancer [ASCO meeting abstracts]. J Clin Oncol 2013; 31 (Suppl):4038.
100. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10:159-165.
101. Zhou WJ, Zhang X, Cheng C, Wang F, Wang XK, Liang YJ, et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol 2012; 166:1669-1683.
102. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-17125.
103. Ramachandran K, Miller H, Gordian E, Rocha-Lima C, Singal R. Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res 2010; 30:3919-3925.
104. Tasaka T, Akiyoshi T, Yamaguchi K, Tanaka M, Onishi H, Katano M. Gammasecretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes. Anticancer Res 2010; 30:4999-5010.
105. McClelland SE, Burrell RA, Swanton C. Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 2009; 8:3262-3266.
106. Ma WW, Hidalgo M. The winning formulation: The development of paclitaxel in pancreatic cancer. Clin Cancer Res 2013; 19:5572-5579.
107. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4:128ra39.
108. Von Hoff DD, Mita M, Eisenberg P, LoRusso P, Weiss G, Sachdev J, et al. A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumors [AACR meeting abstracts]. Proc Am Assoc Cancer Res 2013; LBA203.